Based on these molecular mechanism findings, we screened drugs targeting FASN and SREBF1 from the Cancer Therapeutics Response Portal (CTRP), Genomics of Drug Sensitivity in Cancer (GDSC), and CellMiner databases. Here, FASN is linked to cancer.